Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 204

The DOI matches its Crossref record.

Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma

Open access
Kobe, Carsten, Dietlein, Markus, Franklin, Jeremy, Markova, Jana, Lohri, Andreas, Amthauer, Holger, Klutmann, Susanne, Knapp, Wolfram H., Zijlstra, Josee M., Bockisch, Andreas, Weckesser, Matthias, Lorenz, Reinhard, Schreckenberger, Mathias, Bares, Roland, Eich, Hans T., Mueller, Rolf-Peter, Fuchs, Michael, Borchmann, Peter, Schicha, Harald, Diehl, Volker, Engert, Andreas·2008·Blood

Abstract

In the HD15 trial of the German Hodgkin Study Group, the negative predictive value (NPV) of positron emission tomography (PET) using [18F]-fluorodeoxyglucose in advanced-stage Hodgkin lymphoma (HL) was evaluated. A total of 817 patients were enrolled and randomly assigned to receive BEACOPP-based chemotherapy. After completion of chemotherapy, residual disease measuring more than or equal to 2.5 cm in diameter was assessed by PET in 311 patients. The NPV of PET was defined as the proportion of PET− patients without progression, relapse, or irradiation within 12 months after PET review panel. The progression-free survival was 96% for PET− patients (95% confidence interval [CI], 94%-99%) and 86% for PET+ patients (95% CI, 78%-95%, P = .011). The NPV for PET in this analysis was 94% (95% CI, 91%-97%). Thus, consolidation radiotherapy can be omitted in PET− patients with residual disease without increasing the risk for progression or early relapse compared with patients in complete remission. The impact of this finding on the overall survival at 5 years must be awaited. Until then, response adapted therapy guided by PET for HL patients seems to be a promising approach that should be further evaluated in clinical trials. This trial is registered at http://isrctn.org study as #ISRCTN32443041.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2008-06-155820

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 204

Metadata

Authors
Kobe, C., Dietlein, M., Franklin, J., Markova, J., Lohri, A., Amthauer, H., Klutmann, S., Knapp, W. H., Zijlstra, J. M., Bockisch, A., Weckesser, M., Lorenz, R., Schreckenberger, M., Bares, R., Eich, H. T., Mueller, R.-P., Fuchs, M., Borchmann, P., Schicha, H., Diehl, V., & Engert, A.
Venue
Blood
Published
2008-11-15
Volume
112
Issue
10
Pages
3989-3994
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W1984997204
Cited by
204
References
0
FWCI
18.33
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma. https://app.cochat.ai/papers/10.1182/blood-2008-06-155820
The paper
Kobe, C., Dietlein, M., Franklin, J., Markova, J., Lohri, A., Amthauer, H., Klutmann, S., Knapp, W. H., Zijlstra, J. M., Bockisch, A., Weckesser, M., Lorenz, R., Schreckenberger, M., Bares, R., Eich, H. T., Mueller, R.-P., Fuchs, M., Borchmann, P., Schicha, H., . . . Engert, A. (2008). Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma. Blood. https://doi.org/10.1182/blood-2008-06-155820

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.